Assays. 5.5 In the event that the Applicant has requested that certain assays be conducted on selected Samples (and UK Biobank agrees to conduct such assays on behalf of the Applicant):
Assays. The assays for a particular biomarker to be co-developed under the Technology Development Agreement and/or the Collaboration Agreement by Response and JBT that will run on the New Analyzer.
Assays. (a) From the samples taken from each lot in accordance with Clause 14, the assays of metal and other materials contents shall be determined independently by Dowa and Seller or their respective nominees in accordance with international practice.
Assays. If Gen-Probe (i) fails at any time during the Blood Screening Term to maintain the applicable FDA (CBER) license for the facility used to manufacture a Blood Screening Assay (unless Gen-Probe is approved by CBER to manufacture from an alternative location or the Supervisory Board agrees within fifteen (15) days of such event that Gen-Probe shall retain the manufacturing responsibility hereunder); or (ii) fails to supply Novartis within forty-five (45) days after the requested delivery date with Novartis’s monthly requirements for a Blood Screening Assay ordered in accordance with Section 5.3 below, for any three (3) months in any nine-month period (unless the Supervisory Board agrees within fifteen (15) days of such event that Gen-Probe shall retain the manufacturing responsibility hereunder), then Novartis shall have the right to, and if Novartis elects to manufacture or have manufactured, the obligation to use Commercially Reasonable Efforts to, manufacture (or to have manufactured) its requirements of such Blood Screening Assay, to be conducted by the Blood Screening Instruments in the Territory for use in the Blood Screening Field; provided, however, such right of Novartis shall be on an assay-by-assay basis for a failure to supply. In such event, Novartis shall consider in good faith, as its preferred alternative upon Gen-Probe’s request, to take over control of and responsibility for the facility used by Gen-Probe to manufacture the Blood Screening Assays, and Gen-Probe promptly shall provide such reasonable technical assistance, at Gen-Probe’s sole cost, as necessary to enable Novartis to exercise its rights to manufacture (or have manufactured) such Blood Screening Assay.
Assays. Buyer represents and warrants that it does not intend to use any assays to be acquired or licensed from Seller, including those assays that are part of the GPCR Directed Chemistry Program, in a method to identify and select compounds infringing any of the claims of United States Patent No. 5,401,629, so long as such claim(s) remain outstanding and in effect.
Assays. From the samples taken Buyer and Seller shall each make their own assays results which shall be exchanged in the customary or mutually agreed manner no later than seventy five (75) days from the date of the weight certificate at the smelter pursuant to the shipment. All assays (including any umpire assays) shall show copper content to the nearest 1/100 of one percent, gold content to the nearest 1/10 of a gram per dry metric ton, and silver content to the nearest one gram per dry metric ton, respectively. All assays for precious metals shall be undertaken using the fire assaying technique and shall be adjusted for cupellation losses. All assays for precious metals will be based on a mutually agreed practice & subject to review from time to time. The average of Buyer's and Seller's assays shall govern settlement unless the following splitting limits if applicable, are exceeded: Copper 0.25 percent, Silver 10 grams per DMT and Gold 0.30 grams per DMT. Reference to an Umpire shall be mutual agreement from an agreed list given below. The umpires in the list may be changed from time to time by mutual agreement. The arithmetic mean of the umpire assay and the nearest assay shall be final for settlement. The cost of the umpire assay shall be for the account of the party whose assay is farthest from the umpire assay. If the umpire assay is the exact mean of the Buyer's and Seller's assays the cost of the umpire shall be divided equally. THE UMPIRE LIST
Assays. Exelixis hereby grants BMS an exclusive, worldwide, royalty-bearing (solely to the extent provided in Section 7.4) license (with the right to sublicense), under any EXEL Know-How and EXEL Patents covering the composition or use of one (1) or more Assays, (A) to make and have made such Assay, (B) to use each such Assay to search for, make and have made (1) Collaboration Compounds with activity against the BMS Selected Target for which such Assay was developed, and (2) compounds that lack activity against the BMS Selected Target for which such Assay was developed, (C) to develop, and make or have made, for use in the Development Field (and in any defined field licensed by BMS under Section 5.2(b)(iii)), BMS Collaboration Products, and (D) to develop, following the commencement of a clinical trial of a BMS Collaboration Product in the Development Field, such BMS Collaboration Product for any human indication. Such license shall convert to a non-exclusive license, on an Assay-by-Assay basis, on the earlier of (x) the date that is [ * ] after the end of the Research Term, or (y) the BMS Selected Target relating to such Assay becomes an Abandoned Target and is selected by Exelixis as an EXEL Selected Target.
Assays. So long as BMS’ rights under Section 5.1(a)(iii) remain exclusive, BMS hereby grants Exelixis a non-exclusive, worldwide royalty-free license (without the right to sublicense except to its Affiliates), under the EXEL Know-How and EXEL Patents covering the composition or use of a given Assay solely to use such Assay pursuant to a Work Plan agreed to by BMS and Exelixis under Section 3.5(b) where Exelixis will use such Assay to perform high throughput screening to identify compounds which have or lack activity against the Selected Target for which such Assay was developed.
Assays. Thyroid hormones, thyroid-stimulating hormone (TSH), and urinary creatinine and catecholamines concentrations were determined using standardized routine methodology at the clinical chemistry laboratories of the LUMC. FT4 was measured on an IMx (Abbott, Xxxxxx Park, IL; intra-assay variability: 2.5-7.6%, interassay variability: 5.6-12.4%) at different levels). Total T4 was determined on the TDx (Abbott; interassay CVs: 2.4-5.9%). Free tri-iodothyronine (FT3) was measured by RIABEAD (Abbott; interassay CVs of 2.0-4.4%). Serum TSH was determined with a Modular Analytics E-170 system (Roche Diagnostic Systems, Basle, Switzerland), interassay variability:0.88- 10.66%). Reference values for FT4, FT3 and TSH are respectively 10-24 pmol/L, 2.5-5.4 pmol/ L and 0.4-4.8 mU/L. Urinary norepinephrine (NE), dopamine (DOPA) and vanillylmandelic acid (VMA) were determined by routine HPLC methodology. Statistical analysis Data are expressed as mean ± standard deviation (SD). For assessment of the treatment effect between groups, the variables were log-transformed to meet the requirements for analysis of variance. Subsequently the transformed data were analyzed using analysis of covariance (ANCOVA, SAS Proc MIXED) with the baseline value as co-variate. Treatment least square means were back-transformed resulting in geometric mean treatment estimates corrected for differences in the baseline values. Contrasts and 95% confidence intervals (95% CI) between treatments were back-transformed resulting in geometric mean ratios, which were subsequently translated into percentage increase of the therapy treatment relative to the maintenance treatment. The data obtained at baseline in the subclinical hyperthyroidism patient cohort were compared with data obtained in patients with overt hyperthyroidism and healthy controls using ANOVA and unpaired Student’s t-test assuming unequal variances. The latter data were obtained using similar methodology and were reported earlier by our group (5). These data were also used to perform a post-hoc power analysis (using power=80% and alpha=5%) to calculate the required sample size per group for detecting relevant changes in the study parameters. Relevant changes were defined as the change required for normalizing the values obtained in the subclinical hyperthyroidism patients to the values observed in healthy controls. All analyses were performed using SAS software (V9.1.2, SAS Institute, Inc., Cary, NC, USA). Results Patient characteristics Thir...
